BRPI0419179A - formulação de alta dosagem de liberação prolongada de gepirona - Google Patents

formulação de alta dosagem de liberação prolongada de gepirona

Info

Publication number
BRPI0419179A
BRPI0419179A BRPI0419179-0A BRPI0419179A BRPI0419179A BR PI0419179 A BRPI0419179 A BR PI0419179A BR PI0419179 A BRPI0419179 A BR PI0419179A BR PI0419179 A BRPI0419179 A BR PI0419179A
Authority
BR
Brazil
Prior art keywords
gepirone
high dosage
present
release formulation
prolonged release
Prior art date
Application number
BRPI0419179-0A
Other languages
English (en)
Inventor
Stephen J Kramer
Louis F Fabre
Original Assignee
Fabre Kramer Pharmaceuticals I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Pharmaceuticals I filed Critical Fabre Kramer Pharmaceuticals I
Publication of BRPI0419179A publication Critical patent/BRPI0419179A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO DE ALTA DOSAGEM DE LIBERAçãO PROLONGADA DE GEPIRONA. A presente invenção se refere a formulação de gepirona de liberação prolongada de alta dosagem e métodos para tratar major depressão administrando a mesma a um sujeito que necessite da mesma. Mais especificamente, a presente invenção se refere a uma forma de comprimido de gepirona de liberação prolongada de alta dosagem. A presente invenção também se refere a um método para tratar depressão em mamíferos administrando a um sujeito que necessite da mesma uma quantidade eficaz a formulação de gepirona de liberação prolongada de alta dosagem de acordo com a presente invenção.
BRPI0419179-0A 2004-11-05 2004-11-05 formulação de alta dosagem de liberação prolongada de gepirona BRPI0419179A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (1)

Publication Number Publication Date
BRPI0419179A true BRPI0419179A (pt) 2007-12-18

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419179-0A BRPI0419179A (pt) 2004-11-05 2004-11-05 formulação de alta dosagem de liberação prolongada de gepirona

Country Status (11)

Country Link
EP (1) EP1809255A4 (pt)
JP (1) JP2008519071A (pt)
CN (1) CN101076320A (pt)
AU (1) AU2004324868B2 (pt)
BR (1) BRPI0419179A (pt)
CA (1) CA2585606A1 (pt)
EA (1) EA013213B1 (pt)
IL (1) IL182792A0 (pt)
MX (1) MX2007005368A (pt)
NO (1) NO20072851L (pt)
WO (1) WO2006052227A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (it) 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
RU2713725C1 (ru) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Биологически активная добавка и способ ее применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
KR20040018314A (ko) * 2000-12-08 2004-03-03 악조 노벨 엔.브이. 게피론을 함유하는 경구 투여용 연장 방출형 제제
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Also Published As

Publication number Publication date
NO20072851L (no) 2007-07-31
WO2006052227A1 (en) 2006-05-18
CN101076320A (zh) 2007-11-21
JP2008519071A (ja) 2008-06-05
IL182792A0 (en) 2007-08-19
MX2007005368A (es) 2007-09-11
EP1809255A4 (en) 2011-08-03
EA200701010A1 (ru) 2007-10-26
AU2004324868B2 (en) 2010-04-29
CA2585606A1 (en) 2006-05-18
EA013213B1 (ru) 2010-04-30
EP1809255A1 (en) 2007-07-25
AU2004324868A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
BRPI0606393A2 (pt) prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
CO6400186A2 (es) Tabletas de acetato de ulipristal
BRPI0622054B8 (pt) composto e composição farmacêutica
CR11724A (es) Agente para tratar enfermedades
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
PA8815501A1 (es) Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
CU20110080A7 (es) Formulación farmacéutica 514
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
GT200900089A (es) Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]